# 3D Medicines

Source: https://onco.cc/companies/3d-medicines/  
OnCo record `3d-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

3D Medicines is a Chinese biotechnology company that co-developed envafolimab, the first subcutaneous PD-L1 antibody, approved in China in 2021 for microsatellite instability-high solid tumours.

## Summary

3D Medicines, headquartered in Sichuan with research in Shanghai and listed in Hong Kong since 2022, develops immuno-oncology antibodies. With Alphamab Oncology and Tracon it brought envafolimab (KN035), a single-domain PD-L1 antibody given by subcutaneous injection, to approval in China in November 2021 for previously treated MSI-high or dMMR advanced solid tumours, and it runs phase 3 trials of the drug in combination with chemotherapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: 3D Medicines (Sichuan) Co., Ltd.; 3D Medicines Inc.; 思路迪
- Tags: ctgov-sponsor
- HQ: Chengdu
- Type: biotech

## Sources

- ClinicalTrials.gov: trials led by 3D Medicines: https://clinicaltrials.gov/search?lead=3D%20Medicines

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Envafolimab](https://onco.cc/drugs/envafolimab/)
- companies: [Alphamab Oncology](https://onco.cc/companies/alphamab/)

---
JSON: https://onco.cc/api/v1/entities/3d-medicines.json